The AllCells Blog

AllCells Blog

AllCells blog posts are dedicated to highlighting scientific trends, innovation, and technological advances within the biomedical industry. Data-driven studies and primary research are conducted to create our blogs and include experts within the following fields: immuno-oncologists, cell and gene therapy, academia, government, and contract research organizations.

Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies

September 21, 2022

Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest […]

Dual Mobilization Enhances CD34+ Yield Across All Donor Types

August 1, 2022

Dual Mobilization Enhances CD34+ Yield Across All Donor Types Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for […]

The Therapeutic Potential of HSC-based Gene Therapies

July 25, 2022

The Therapeutic Potential of HSC-based Gene Therapies Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This […]

A Decade of Innovation: CAR-T Successes and Latest Developments

July 6, 2022

A Decade of Innovation: CAR-T Successes and Latest Developments After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy […]

Cell Therapy

Why You Should Start Clinical Grade Cell Supply Discussions Early in Cell and Gene Therapy Development

May 24, 2022

Why You Should Start Clinical Grade Cell Supply Discussions Early in Cell and Gene Therapy Development Cell and gene therapies represent an expanding category of transformative medicines with the potential […]

Dna Double Helix

What You Need to Know About Regenerative Medicine in 2022: Industry and Tech Trends

April 20, 2022

What You Need to Know About Regenerative Medicine in 2022: Industry and Tech Trends Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed […]

AllCells Opens a New Collection Facility in Houston, Texas

March 29, 2022

AllCells Opens a New Collection Facility in Houston, Texas Expanding Its Donor Network AllCells, the leading provider of human hematological products and services, is pleased to announce the opening of […]

Donor Management Services

A Donor-Centric Approach to Cell and Gene Therapy

February 3, 2022

In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While […]

*

AllCells Announces First to Market Launch of In Stock GMP-Compliant Cryopreserved Leukopaks

January 28, 2022

Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time AllCells, the industry leader in the […]

AllCells cryopreserved cells in vial

FAQ Series: The Science Behind Cryopreservation

January 11, 2022

Primary cells, such as those isolated from the bone marrow or peripheral blood, are important for a wide scope of research and clinical applications – from studying molecular mechanisms driving disease progression, to […]

Subscribe to Our Blog

Stay current with the AllCells Blog. Get email updates with helpful resources for biomedical researchers:

Customer Service

How Can We Help You?


Looking for research tips? Need help sourcing materials? How about a few more articles on therapies or processes? At AllCells, we believe that partnerships create the best pathways to success. Our Customer Success Team has years of industry experience and a wealth of resources to help you get the most out of your cellular products. We’re only a few clicks away.

Contact Us
Have a question? Let’s chat.